Nanobiotix (NBTX) announces the launch, subject to market and other conditions, of an approximately EUR 75M global follow-on offering consisting of (i) a public offering of its American Depositary Shares, each ADS representing one ordinary share, EUR0.03 nominal value per share, of the company, in the United States and (ii) an offering of (a) its Ordinary Shares and (b) pre-funded warrants to subscribe for Ordinary Shares, exclusively addressed to “qualified investors” in Europe within the meaning of Article 2(e) of Regulation (EU) 2017/1129, as amended, and certain other countries. Jefferies, TD Cowen and Stifel are acting as global coordinators and joint bookrunners for the Global Offering.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBTX:
- Nanobiotix files EUR75M ordinary shares offering
- Nanobiotix Reports Promising Phase 2 Data for NBTXR3 in Stage 3 Inoperable Lung Cancer
- Nanobiotix price target raised to EUR 60 from EUR 34 at H.C. Wainwright
- Nanobiotix Fast-Tracks Pivotal Head and Neck Cancer Trial with FDA-Backed Protocol Shift
- Nanobiotix announces FDA acceptance of NANORAY-312 study protocol amendment